Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TNG260 · 1 trial · 4 indications
To determine the MTD and RP2D(s) of TNG260 when administered in combination with pembrolizumab
To assess antineoplastic activity of TNG260 when administered in combination with pembrolizumab in participants with locally advanced unresectable or metastatic STK11-mutated solid tumors by measuring ORR, DOR, and PFS by RECIST 1.1
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | Participants with STK11-mutant solid tumors will receive escalating doses of TNG260 in combination with pembrolizumab to estimate the MTD |
| Dose Expansion in NSCLC with KRAS Mutation | EXPERIMENTAL | Participants with STK11-mutant and KRAS-mutant NSCLC (squamous and non squamous) will receive TNG260 at the identified RP2D in combination with pembrolizumab |
| Dose Expansion in NSCLC with KRAS Wild type | EXPERIMENTAL | Participants with STK11-mutant and KRAS-wild type NSCLC (squamous and non-squamous) will receive TNG260 at the identified RP2D in combination with pembrolizumab |
| Dose Expansion in Advanced or Metastatic Solid Tumors | EXPERIMENTAL | Participants with STK11-mutant solid tumors (including but not limited to pancreatic, endometrial, cervical, breast, and carcinoma of unknown primary) will receive TNG260 at the identified RP2D in combination with pembrolizumab |
| Name | Type | Description |
|---|---|---|
| TNG260 | DRUG | CoREST inhibitor, administered orally |
| Pembrolizumab | DRUG | Pembrolizumab, an anti-PD-1 antibody, administered intravenously |
Inclusion Criteria: * Is ≥18 years of age at the time of signature of the main study ICF. * Has ECOG performance status of 0 or 1. * Has measurable disease based on RECIST v1.1. * All participants must have documented STK11 mutation in a solid tumor, which is identified through a validated analytic...
Top 20 of 84 competitors
TNG260 is an investigational small molecule being studied for the treatment of non-small cell lung cancer and other solid tumors. It is currently in Phase 1 clinical development and is not yet approved by the FDA.
TNG260 targets the CoREST complex, a protein complex involved in gene regulation. By inhibiting this complex, the drug aims to modulate cancer cell behavior, particularly in tumors with STK11 mutations.
TNG260 is being developed by Tango Therapeutics, Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol TNGX.
TNG260 is currently in Phase 1 clinical trials. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical evaluation for safety and efficacy.
TNG260 is being studied in a Phase 1 clinical trial with the identifier NCT05887492. This trial is investigating TNG260 in combination with an anti-PD antibody in patients with STK11-mutated solid tumors, including non-small cell lung cancer.
TNG260 is a unique investigational compound developed by Tango Therapeutics. No alternative names for this drug have been reported in clinical trial registries.